Table 4.

Days to Resolution of Symptoms (Primary Endpoint) by Use of Oseltamivir

N (%)	Placebo Median [Q1, Q3] or Mean ± SD N (%)	Elderberry Median [Q1, Q3] or Mean ± SD	p value*
Not taking oseltamivir, 43 (51)	5.1 ± 2.5 26 (60)	7.3 ± 3.4 17 (40)	0.02†
Age ≤12 years, 15 (35)	5.4 ± 2.4 10 (67)	8.2 ± 2.8 5 (33)	0.06†
Age ≥ 13 years, 28 (65)	4.9 ± 2.6 16 (57)	6.9 ± 3.7 12 (43)	0.11†
Taking oseltamivir 42 (49)	4.0 [3.0, 6.0]	3.0 [2.0, 5.0]	0.35†
Age ≤ 12 years 19 (45)	4.0 [2.0, 6.0] 8 (42)	2.0 [2.0, 3.0] 11 (58)	0.27
Age ≥ 13 years 23 (55)	4.0 [3.0, 5.0] 9 (39)	3.0 [3.0, 6.0] 14 (61)	0.99

*Unless otherwise indicated, days to symptom resolution was tested with a two-sample Wilcoxon rest

†Student’s t test